Catalent, Inc. (CTLT) recently entered a strategic partnership with Siren Biotechnology. The tie-up aims to support the development and manufacturing of Siren Biotechnology’s adeno-associated viral (AAV) immuno- gene therapies. The latest partnership is expected to be a significant stepping stone for its Biologics business and solidify its foothold in the niche space. Rational Behind the Collaboration Under the partnership, Catalent will provide process development and cGMP (current good manufacturing pract ...